%0 Journal Article
%T M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s
%A Dong Huang
%A Fei Gao
%A Jianquan Li
%A Jun-Yong Huang
%A Nanmao Dang
%A Nuria Martinez-Lopez
%A Paul A. Jowsey
%A Robert N. Lightowlers
%J Archive of "Cell Division".
%D 2019
%R 10.1186/s13008-019-0049-5
%X M2I-1 promotes the sensitivity of cancer cell lines to anti-mitotic drugs. HeLa cells were treated with one of 0.5% DMSO, 50 ¦ÌM M2I-1, 60 ng/ml nocodazole, or 60 ng/ml nocodazole£¿+£¿50 ¦ÌM M2I-1 in a 24-well plate for 16 h. Digital images of cells from three or four random areas of each well were taken using a digital camera mounted on a tissue culture microscope with a 20x objective lens and used to quantify the mitotic and apoptotic indices. a Sample images showing non-mitotic cells (arrows), normal mitotic cells (arrowheads), mitotically arrested cells (dash line arrows), and apoptotic cells (asterisk). b, d Apoptotic indices quantified from HeLa cells treated with 60 ng/ml (equivalent to 200 nM) nocodazole or 30 nM Taxol under different circumstances as indicated. c, e Mitotic indices quantified from HeLa cells treated with 60 ng/ml nocodazole or 30 nM Taxol under the circumstances indicated. f Apoptotic indices quantified from A549, HT-29 and U2OS cells under the same conditions as described above. All the quantitative data were produced from four independent experiments. n, total cell numbers used for quantification; Noc, nocodazole; M2I-1, MAD2 inhibitor-1. P value: *<£¿0.017; **< 0.001; ***< 0.0003; ****<£¿0.000
%K M2I-1
%K Cyclin B1
%K MCL-1
%K Nocodazole
%K Taxol
%K Apoptosis
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570884/